Sleuth Insights

Andrew Pannu, a seasoned biopharma analyst and bioeconomy influencer, recognized a systemic inefficiency plaguing the life sciences sector. Despite the industry's reliance on cutting-edge science for drug discovery, the strategic business decisions—often involving billions of dollars in investment and development—were tethered to archaic, manual processes. Stakeholders were forced to depend on slow, expensive consultant reports or fragmented databases to navigate the complex landscape of clinical trials, regulatory filings, and market dynamics. Pannu saw an opportunity to revolutionize this workflow by marrying deep industry expertise with advanced machine learning.

In 2023, this vision came to life with the founding of Sleuth Insights. Headquartered in San Francisco, the company set out to build a modern intelligence layer for the industry, but with a core of agentic AI that goes beyond simple data aggregation. The team developed a proprietary knowledge graph that now houses over 100 million pre-linked entities, creating a living map of the entire biopharmaceutical ecosystem. This technology connects the dots between drugs, trials, deals, modalities, and companies, continuously validating data from diverse sources including patents, conference abstracts, and analyst research.

What started as a bold idea to automate competitive diligence has evolved into a comprehensive AI platform that serves as a force multiplier for biopharma teams. Sleuth Insights replaces the 'data dumps' of the past with tailored, high-fidelity intelligence delivered in real-time. By enabling users to query this vast knowledge graph in natural language, the company has democratized access to high-level strategic insights, allowing executives to prioritize indications and evaluate market positioning with unprecedented speed and accuracy. Today, Sleuth Insights stands at the forefront of the industry's digital transformation, helping some of the world's largest pharmaceutical companies make faster, smarter decisions that ultimately accelerate the delivery of life-saving therapies to patients.